Royalty Pharma

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Genetic,Research,Scientist,Using,Microscope,In,An,Applied,Science,Laboratory

Biotech

Large Cap

News

Health Care

Financing

General

RPRX

RVMD

Revolution Medicines signs a $2 billion funding deal with Royalty Pharma to support its RAS(ON) pipeline, including daraxonrasib development and launch.

Revolution Medicines To Advance Lead Cancer Drug With $2 Billion In Funds


The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing

4 Healthcare Stocks With Massive Gains—and More to Come

Biogen - logo

Earnings

Guidance

Contracts

Movers

BIIB

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to $250 million in R&amp;D funding from Royalty Pharma.

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&amp;D Funding Pact With Royalty Pharma

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma PLC

Press Releases

Royalty Pharma Appoints Vlad Coric, M.D. to the Company's Board of Directors

Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025

Dividends

Royalty Pharma Declares Second Quarter 2025 Dividend

U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)

Royalty Pharma Reports First Quarter 2025 Results

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma Completes the Acquisition of Its External Manager

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Royalty Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell